Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells - sprookjes - yvandenbroek - TriplyDB

Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells

Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells

http://www.wikidata.org/entity/Q35221988

about

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases Androgen receptor molecular biology and potential targets in prostate cancer Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases Transcriptional activity of c-Jun is critical for the suppression of AR function.Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase.Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.Mechanisms mediating androgen receptor reactivation after castration.Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.MicroRNA Library-Based Functional Screening Identified Androgen-Sensitive miR-216a as a Player in Bicalutamide Resistance in Prostate Cancer.Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer Targeting the androgen receptor pathway in prostate cancer.Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis Posttranslational modification of the androgen receptor in prostate cancer.AR, the cell cycle, and prostate cancer.Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins RNA editing of androgen receptor gene transcripts in prostate cancer cells.Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.Src controls castration recurrence of CWR22 prostate cancer xenografts.Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.Androgen action and metabolism in prostate cancer.Evolution of androgen receptor targeted therapy for advanced prostate cancer.Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling Down-regulation of androgen-receptor and PSA by phytochemicals.Mithramycin targets sp1 and the androgen receptor transcription level-potential therapeutic role in advanced prostate cancer.Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.TREMOR--a tool for retrieving transcriptional modules by incorporating motif covariance.Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells.Reliability of a composite measure of social inclusion for people with psychiatric disabilities.

P2860

Q21558502-9A73ADB6-1529-4D17-AD25-EAF0BFB102F5 Q24602861-B6F25512-C010-4EC6-A509-2AD20F54B766 Q26866135-F1D1E806-1C8E-49B6-ACA1-03837B86136C Q30412500-FC0FCB42-2013-4C15-9BA8-8E9345D2A9ED Q30500293-50F5A911-687F-4D07-827E-43ABE4115F32 Q33968384-15913D48-0BFE-4360-A3AB-08DBBB3D0E3A Q33989603-4CA80C16-DE28-4262-B446-3C550AACCC2C Q34294283-5EA7149D-A763-4079-8CF5-A32E0456B6EA Q34599285-DA778140-29A6-4004-9CEC-6A64B4888AE0 Q35109795-A4F78E59-EE92-4F07-A38B-4A1C15D4D008 Q35633454-1D33209A-F31C-4047-9DC3-6750B6EF97B9 Q35694048-C3112456-279A-449D-AB49-BF64FF5B33DD Q35823109-E7747BCC-60C0-4F67-83E3-3678EDC7E9EF Q35868187-043FA0B7-CBE6-494A-BECD-3B4FC6577075 Q36777961-2F19D869-D1F4-422B-94E7-CB211A41EB5E Q36953028-7BD85ECC-6948-4749-B0F2-6B722A2689AF Q36961208-3D63C166-96EE-45E1-86AA-AD5246D5BAB1 Q37092022-E1A60AE9-2E32-410B-9FD1-E5E4E5922DF5 Q37095260-04B7E210-1D3B-4510-AED6-F82D942504CE Q37098796-66F4C12B-BA2D-41CB-9054-62E8CEAD4678 Q37112738-1EDE60F0-8586-485D-B4D1-0F6A857C467F Q37142544-48E4C605-B6A0-4F86-AAC9-939D5031156E Q37161795-56733E5E-55D2-462A-8024-635FE75FB8BE Q37481145-4F742B10-D9F6-458A-9CB5-49639BA98B97 Q37855836-02FAC242-0347-454B-B199-5CF7DEE8B245 Q37997571-BEFA4851-AFF2-4E75-A32E-4901FB379783 Q38212716-1A0C6922-B0E2-476F-B5AA-96FBE5B8C0EC Q39174448-F36CF1D9-2047-42E5-B099-2BC1D5232CB4 Q39665818-3A6E7770-0021-4F1A-8855-4F71FD19A079 Q40023730-C4814E1F-653B-41BC-884E-7FEA9A70EF45 Q40317888-2CF6ECEC-6FE3-4259-9A6E-191035F61833 Q41592660-E821BD0B-F80F-4C90-9988-1BB64456DD32 Q41835652-CADA3C62-4ADB-4F2D-A571-F6A2C9A7A9DB Q41839868-88B5CE4B-D567-4BB2-9883-954829782E34 Q42277586-117E845F-4EDE-45D1-AC66-CA07C89846EF Q42758453-1A76070F-E543-43B7-8B4C-7E98E675C944 Q51893327-522D760B-2E82-476F-95F9-C5FE5B99DA88

P2860

Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells

http://www.wikidata.org/entity/Q35221988

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Androgen receptor remains crit ...... nt CWR22 prostate cancer cells

@ast

Androgen receptor remains crit ...... nt CWR22 prostate cancer cells

@en

type

label

Androgen receptor remains crit ...... nt CWR22 prostate cancer cells

@ast

Androgen receptor remains crit ...... nt CWR22 prostate cancer cells

@en

prefLabel

Androgen receptor remains crit ...... nt CWR22 prostate cancer cells

@ast

Androgen receptor remains crit ...... nt CWR22 prostate cancer cells

@en

P1433

Q35221988-2A9922E9-E39E-42FB-A5D2-0B5B51672957

P1476

Q35221988-53570814-E920-4CA7-9259-865A2F639DB4

P2093

Q35221988-0F519876-078A-46C1-96BD-C511DBDBD59B

Q35221988-58F012C0-53F2-4775-A39C-D657FC125A9A

Q35221988-7D26F110-50E1-4DA4-A143-D088E32FC987

Q35221988-9B5CFD5E-B9A4-479C-A340-83901A04493B

Q35221988-C3A1BAB3-D396-455A-B812-D7513E3D4A7D

Q35221988-CFE41EAE-01DF-4842-8117-56CA0689837C

Q35221988-D63D37FD-CEFC-47D0-9E92-AB59CEBC60BB

Q35221988-E25249F7-F470-4078-9A46-8E31A0BC1EAE

P2860

Q35221988-0E607B7F-ADC1-45CE-9312-8275AF01D9A4

Q35221988-0F1CF25C-7BB4-4D65-9A52-DEF9CF55CC66

Q35221988-11358D3F-D5BF-4B3E-989B-AF4922203011

Q35221988-12C07AE8-D8C0-4E57-BA4B-8701AD833978

Q35221988-13A457A2-C31B-464F-B1B9-5919808AC45E

Q35221988-2F9F2DAC-9983-45DF-A7FE-4BEF95B834C0

Q35221988-306C11C0-12DF-4FBE-AE94-5E43C14E99F5

Q35221988-3AA9EFFF-A8E8-4EB1-B63C-3861E358604D

Q35221988-4C7BDF6D-6033-4355-8F1A-4D0D6205CD28

Q35221988-572154C3-A01F-48D1-BBE0-86B8ECEE874C

P304

Q35221988-3A191BE0-39B8-48A6-B240-F9D36760505A

P31

Q35221988-BE861618-5C61-48B1-8BD2-81ECD8FB804E

P356

Q35221988-433B94A6-4E2C-4409-86F8-A0A80674954C

P407

Q35221988-C5AE04D5-E0DA-4FED-8049-C26F72BAFBFE

P433

Q35221988-E52318B5-64E9-4897-B95D-FE68BCB8B91B

P478

Q35221988-7247649B-2D0E-4CCE-9C0B-3260D78D896D

P50

Q35221988-AA3A112A-D24A-43CF-9916-70C206A193CE

P577

Q35221988-05C03872-674B-481D-A469-1EC3A663F3D0

P5875

Q35221988-3D31AB57-B349-4AC1-A62D-6212D2533519

P698

Q35221988-C92A9CA3-87D3-438E-B521-21A222C95B9B

P932

Q35221988-6640D7A4-8687-46CE-A843-2429C6B19E82

P356

AJPATH.2006.051047

P1433

The American Journal of Pathology

P1476

Androgen receptor remains crit ...... nt CWR22 prostate cancer cells

@en

P2093

Glenn J Bubley

http://www.w3.org/2001/XMLSchema#string

Hongyun Wang

http://www.w3.org/2001/XMLSchema#string

Michael L Lu

http://www.w3.org/2001/XMLSchema#string

Robert A Borgesi

http://www.w3.org/2001/XMLSchema#string

Steven P Balk

http://www.w3.org/2001/XMLSchema#string

Tao Zhang

http://www.w3.org/2001/XMLSchema#string

Tong Li

http://www.w3.org/2001/XMLSchema#string

Xin Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability

Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity

Molecular determinants of resistance to antiandrogen therapy

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

The development of androgen-independent prostate cancer

Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.

Activation of mitogen-activated protein kinase associated with prostate cancer progression.

SRY interacts with and negatively regulates androgen receptor transcriptional activity.

Molecular biology of the androgen receptor.

Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells.

P304

682-696

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2006.051047

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

169

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6909929

http://www.w3.org/2001/XMLSchema#string

P698

16877366

http://www.w3.org/2001/XMLSchema#string

P932

1698802

http://www.w3.org/2001/XMLSchema#string